Filtered-sunlight phototherapy emerges as a pragmatic and innovative alternative to conventional phototherapy. By harnessing sunlight’s natural blue light spectrum and filtering out harmful ultraviolet and infrared rays, this method offers a potentially safe and effective treatment modality in environments where phototherapy equipment is scarce or unavailable. However, despite its promise, the efficacy and safety parameters of filtered-sunlight phototherapy require robust validation through well-designed clinical studies. The integration of this technique with kangaroo mother care, a method involving continuous skin-to-skin contact between mother and infant, further complicates the treatment landscape but also presents novel possibilities.

Kangaroo mother care, beyond its well-documented benefits in improving thermal regulation, breastfeeding success, and maternal-infant bonding, may add a layer of physiological support conducive to the amelioration of jaundice. This contact promotes increased breastfeeding frequency, facilitating bilirubin excretion via enhanced gut motility, and may stabilize infant physiology, potentially reducing bilirubin toxicity risks. Nevertheless, the interaction between KMC and filtered-sunlight phototherapy has not been systematically explored. Understanding how these approaches may complement or interfere with each other is critical before any widespread recommendations can be safely propagated.

One fundamental technical consideration is the precise calibration of light intensity and spectral quality delivered by filtered sunlight. Phototherapy efficacy hinges on delivering illumination within a narrow wavelength band (around 460-490 nm), which absorbs bilirubin molecules effectively, converting them into water-soluble forms for excretion. Sunlight contains this blue spectrum naturally but is accompanied by ultraviolet (UV) and infrared (IR) light, which could be harmful by causing skin erythema or burns, dehydration, or even increasing oxidative stress. Therefore, filtering mechanisms must be engineered to selectively transmit therapeutic wavelengths while blocking detrimental spectral components. This entails developing affordable, durable, and easily deployable filters, optimized for local climatic conditions and solar variability.

Complementarily, kangaroo mother care operates through biological and environmental mechanisms that support neonatal homeostasis. Skin-to-skin contact maintains thermal stability, reduces metabolic demands, and promotes parasympathetic nervous system activity, which can enhance gastrointestinal function and immune responses. These physiological adjustments may influence the kinetics of bilirubin metabolism and elimination, yet the exact pathways through which KMC effects impact jaundice resolution remain insufficiently understood. This gap in knowledge impinges on clinical guidance regarding the optimal timing and duration of combined interventions.

The current evidence base for filtered-sunlight phototherapy is largely derived from observational studies and pilot trials, often lacking rigorous control groups or standardized protocols. Likewise, KMC’s impact on neonatal jaundice has been anecdotal or secondary to its general benefits. Thus, the synthesis of these methodologies necessitates carefully designed randomized controlled trials with adequate sample sizes to elucidate not only efficacy and safety but also long-term neurodevelopmental outcomes. Additionally, socio-cultural acceptability and caregiver adherence are pivotal factors influencing the practical implementation of such combined care models in diverse settings.

Addressing the infrastructural challenges in low-resource contexts is indispensable. Facilities frequently lack reliable electricity, climate control, and access to trained healthcare personnel required for conventional phototherapy. Filtered-sunlight phototherapy could leverage the ubiquitous nature of sunlight, but requires integration into clinical pathways that ensure monitoring of illumination intensity, infant hydration status, and thermal comfort. Kangaroo mother care aligns well with such limitations by minimizing dependence on equipment and fostering maternal involvement. However, overlapping these two interventions raises questions about how infant positioning may impact light exposure uniformity and treatment dosage, necessitating methodological scrutiny.

From an engineering perspective, innovations in portable phototherapy units that incorporate natural light filtering technologies represent an exciting frontier. Such devices ideally provide consistent spectral quality irrespective of environmental fluctuations and integrate user-friendly mechanisms for real-time monitoring of phototherapy dose. Coupling these units with caregiver education programs emphasizing safe and effective bilayered care modalities could revolutionize neonatal jaundice management. Yet, the scalability and sustainability of manufacturing, distributing, and maintaining these technologies require partnerships between academia, industry, public health authorities, and community stakeholders.

Clinicians and researchers must also consider potential contraindications or complications arising from combined filtered-sunlight phototherapy and KMC. For instance, prolonged sunlight exposure, even when filtered, could theoretically increase risks of erythema or hyperthermia, particularly in preterm or low-birth-weight infants with immature skin barriers. Simultaneously, KMC relies on maternal capacity and willingness, which may be compromised by fatigue, social responsibilities, or limited health literacy. Developing comprehensive protocols that balance phototherapy dosage, duration, and infant monitoring with KMC practices is imperative to maximize benefits and minimize harms.

The policy implications of this combined intervention strategy are profound. Health systems aiming to reduce neonatal morbidity and mortality must adjudicate resource allocation, training programs, and health education campaigns that accommodate these integrative approaches. Moreover, successful demonstration of efficacy could catalyze endorsement by global health bodies such as WHO, influencing guidelines and funding priorities. This necessitates prompt action in conducting multi-center trials and disseminating robust data to inform evidence-based policymaking.

In sum, the convergence of filtered-sunlight phototherapy and kangaroo mother care underscores a compelling paradigm shift in neonatal jaundice management tailored for low-resource settings. It harnesses natural resources and maternal caregiving to address a ubiquitous clinical challenge with potentially transformative outcomes. Yet, the path forward demands rigorous interdisciplinary research to navigate the complexities inherent in technology development, physiological interactions, and implementation science. Only through such concerted efforts can we hope to effect meaningful improvements in neonatal health equity worldwide.

As we stand on the cusp of this innovative horizon, the scientific and medical communities are called upon to meticulously unravel the mechanistic nuances and clinical efficacy of this dual intervention. Detailed photobiological investigations alongside comprehensive neonatal physiology assessments must underpin clinical trial designs. The translational journey from bench to bedside, and ultimately community, hinges on decoding these interconnected dynamics. Engagement with local populations and stakeholders will be critical to tailor interventions culturally and contextually, ensuring adherence and maximizing impact.

Moreover, future research must extend beyond immediate therapeutic outcomes to evaluate neurodevelopmental trajectories and quality of life metrics, thereby capturing the full spectrum of benefits and risks. The integration of emerging digital health tools could facilitate monitoring and data collection, enhancing trial robustness and feedback loops for continual improvement. Ultimately, the goal is not merely to introduce a novel therapeutic combination but to establish a sustainable, accessible, and efficacious standard of care that aligns with the realities faced by millions of vulnerable neonates and their families globally.

The intersection of filtered-sunlight phototherapy and kangaroo mother care exemplifies innovative thinking aligned with socioeconomic and environmental pragmatism. While barriers remain substantial, this approach signifies a beacon of hope that judicious exploitation of natural phenomena combined with human touch can redefine neonatal care paradigms. The call to action is clear: accelerate research, foster collaborations, and embrace interdisciplinary innovations to transform these promising hypotheses into tangible health gains that transcend traditional limits of resource availability.

In this evolving narrative, the stakes transcend clinical outcomes, touching upon equity, sustainability, and the fundamental human right to health. As we advance this frontier, it is imperative to maintain scientific rigor while honoring the lived experiences of communities most impacted. Through this balanced approach, filtered-sunlight phototherapy coupled with kangaroo mother care may yet emerge as a cornerstone of neonatal jaundice management in the 21st century.

Subject of Research: Neonatal jaundice management through combined filtered-sunlight phototherapy and kangaroo mother care in low-resource settings.

Article Title: Combining filtered-sunlight phototherapy with kangaroo mother care in low-resource settings: further research needed.

Article References:
Emokpae, A.A., Omololu, O.M. & Olusanya, B.O. Combining filtered-sunlight phototherapy with kangaroo mother care in low-resource settings: further research needed. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-04991-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-04991-9

Historically, neonatal jaundice—a condition resulting from elevated bilirubin levels—has been managed primarily through assessing total serum bilirubin. Bilirubin, a breakdown product of hemoglobin metabolism, circulates in the blood both bound to albumin and in an unbound, free form. It is the unbound fraction of bilirubin that possesses neurotoxic potential, capable of crossing the blood-brain barrier and causing devastating consequences such as kernicterus. Despite this, clinical protocols have largely depended on TSB thresholds, which may underestimate a neonate’s risk, especially in vulnerable populations.

Dr. Hegyi posits that the molecular dynamics of bilirubin-albumin interactions hold the key to better understanding and predicting bilirubin-induced neurotoxicity. Albumin acts as a transport protein, sequestering bilirubin and limiting its access to tissues. However, factors such as albumin concentration, binding affinity alterations due to competing substances or neonatal pathophysiology, and the intrinsic variability in bilirubin’s dissociation rate create a complex biochemical landscape. This variability makes total bilirubin an insufficient surrogate marker for potential brain injury risk, underscoring the necessity for direct measurement of unbound bilirubin levels.

Advancements in analytical techniques have finally made it feasible to accurately quantify unbound bilirubin. These methodologies include high-sensitivity fluorescence assays and ultrafiltration combined with chromatographic separation, enabling clinicians to detect free bilirubin in real-time. Dr. Hegyi highlights the pivotal role these technologies can play in tailoring phototherapy and exchange transfusion decisions, potentially reducing unnecessary interventions and preventing irreversible neurotoxicity by intervening precisely when unbound bilirubin reaches hazardous levels.

The article sheds light on several clinical scenarios in which unbound bilirubin measurement vastly outperforms TSB. For instance, in preterm infants or those with hypoalbuminemia, the total serum bilirubin might appear deceptively low, masking a significant neurotoxic threat posed by increased free bilirubin fractions. Similarly, in the presence of certain drugs or endogenous metabolites that competitively displace bilirubin from albumin, total bilirubin fails to predict the augmented risk. Here, unbound bilirubin serves as a critical biomarker to flag neonates who might otherwise be misclassified as low risk.

In examining the pathophysiological underpinnings, Dr. Hegyi elaborates on the mechanisms by which unbound bilirubin crosses cellular membranes. Its lipophilic nature facilitates penetration through the blood-brain barrier, where it interferes with mitochondrial function and induces oxidative stress in neurons. Such molecular insights provide a rationale for why some infants develop bilirubin-induced neurological dysfunction despite seemingly moderate total bilirubin levels, emphasizing that free bilirubin toxicity is a kinetic and dynamic process beyond mere concentration thresholds.

The call to action is not just about adopting new diagnostic tools but also about re-envisioning clinical frameworks that guide neonatal jaundice treatment. Dr. Hegyi stresses the integration of unbound bilirubin measurement into routine newborn screening protocols and treatment algorithms. By doing so, health systems can stratify risk more precisely, personalize therapeutic interventions, and minimize overtreatment that may carry its own risks, such as phototherapy-associated side effects or procedural trauma from exchange transfusions.

Moreover, the article critically reviews current guidelines from leading pediatric organizations, which predominantly rely on total bilirubin charts. Dr. Hegyi suggests these guidelines are overdue for revision to incorporate evidence emerging on unbound bilirubin’s prognostic superiority. He points out that a restructured guideline would empower clinicians to act decisively based on a biomarker that reflects the actual toxic entity, thereby improving clinical outcomes and reducing long-term sequelae in affected infants.

From a research perspective, the article proposes an urgent need for large-scale, multicenter clinical trials to validate the efficacy and safety of protocol changes emphasizing unbound bilirubin monitoring. Such investigations will not only solidify the biomarker’s role but also evaluate cost-effectiveness, feasibility, and the potential to reduce healthcare burdens by preventing bilirubin encephalopathy more effectively.

Dr. Hegyi also addresses potential barriers, including the availability of unbound bilirubin assays in various healthcare settings, cost implications, and the requirement for clinician education. Bridging these gaps will demand concerted efforts from medical device manufacturers, policymakers, and neonatal care providers. Ensuring accessibility and accurate interpretation of unbound bilirubin values will be crucial steps toward universal adoption.

In summary, this enlightening article challenges the clinical community to rethink the management of neonatal jaundice through a molecularly informed lens, focusing on unbound bilirubin as the true culprit behind neurotoxicity. It promises a new era where neonatal care is not only reactive but anticipatory and precision-driven, minimizing the risk of lifelong disabilities emanating from bilirubin toxicity.

This shift in paradigm holds particular promise for resource-limited settings where neonatal mortality and morbidity from jaundice remain disproportionately high. With appropriate technological dissemination and training, unbound bilirubin measurement could become a key element in global newborn health initiatives, potentially transforming outcomes on a worldwide scale.

In essence, Dr. Hegyi’s paper not only offers a scientific advancement but advocates a philosophical transformation in neonatal medicine. It prompts clinicians to move beyond traditional metrics, embracing a more sophisticated and nuanced understanding of bilirubin toxicity and its clinical manifestations.

As biomedical research continues to unravel the complexities of bilirubin physiology, unbound bilirubin stands out as a biomarker bridging molecular pathology with bedside care, exemplifying how modern diagnostics can enhance both science and humanity. The neonatal community awaits these changes with optimism, envisioning a future where jaundice is managed with unprecedented accuracy and compassion.

The publication sets a high bar for neonatal research, encouraging cross-disciplinary collaboration among biochemists, neonatologists, and clinical laboratory scientists to refine tools that measure unbound bilirubin and integrate them seamlessly into clinical environments.

Ultimately, this pioneering work is a clarion call, inspiring stakeholders to recalibrate neonatology practices, prioritize infant brain health, and reduce the global burden of bilirubin-related morbidity through innovation grounded in molecular insight.

Subject of Research: Neonatal bilirubin management focusing on unbound bilirubin measurement and its implications for clinical decision-making.

Article Title: Unbound bilirubin: a call to reframe neonatal care and clinical decision-making.

Article References:
Hegyi, T. Unbound bilirubin: a call to reframe neonatal care and clinical decision-making. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04667-w

Image Credits: AI Generated

DOI: 10.1038/s41390-025-04667-w

Jaundice in newborns is primarily caused by an excess of bilirubin, a yellow pigment produced during the breakdown of red blood cells. While jaundice often resolves on its own, severe cases can lead to significant complications, including kernicterus, which can cause permanent neurological damage. Therefore, timely assessment and intervention are critical. The authors of this study aim to develop a predictive model for determining which infants are at risk of requiring phototherapy, a common treatment that utilizes light to reduce bilirubin levels in the blood.

The study meticulously outlines the method used to gather and analyze data from neonates, focusing on early postnatal capillary blood samples to measure end-tidal carbon monoxide (ETCOc) levels. ETCOc is a promising biomarker, as it correlates with the level of bilirubin and can be indicative of hemolysis, the breakdown of red blood cells. By establishing a relationship between ETCOc levels and the progression of jaundice, the researchers present a pioneering approach to anticipating the need for treatment.

As part of their comprehensive analysis, the research team deployed a robust statistical framework to validate the predictive accuracy of ETCOc levels. They conducted a series of tests to assess how well ETCOc could serve as a precursor to elevated bilirubin levels that necessitate phototherapy intervention. Their findings revealed a striking correlation, suggesting that clinicians could significantly benefit from incorporating ETCOc measurements into standard practice.

This innovative predictive model offers a dual benefit: it enables healthcare providers to identify at-risk newborns early while also potentially reducing unnecessary treatments for those who may not require phototherapy. In a healthcare landscape that increasingly emphasizes personalized medicine, this approach aligns perfectly with the broader goal of tailoring interventions based on individual patient needs. With jaundice being a prevalent condition impacting a vast number of newborns globally, such advancements could have far-reaching implications.

The implications of this research extend beyond China, as the methodology could be adapted for use in diverse healthcare systems worldwide. This adaptability foreshadows a future wherein early detection methods for jaundice become standardized, ultimately improving outcomes and reducing the burden on healthcare facilities. By employing a more refined approach to identifying infants at risk, clinicians can focus resources on those who truly need them, thereby optimizing neonatal care.

The study’s outcomes highlight the importance of interdisciplinary collaboration in addressing neonatal health issues. Researchers from various backgrounds—including neonatology, biostatistics, and pediatrics—contributed their expertise toward refining the predictive model. This collaborative spirit serves as a testament to the progress that can be achieved when experts unite around a common goal, fostering innovation that enhances patient care.

Moreover, the research emphasizes the necessity for ongoing education among healthcare professionals regarding the latest advancements in neonatal care. As new evidence emerges, it becomes imperative for practitioners to stay informed and adapt their practices accordingly. The introduction of ETCOc as a predictive marker for phototherapy signifies an important shift in how clinicians can approach neonatal jaundice, ensuring that they provide optimal care while minimizing exposure to unnecessary interventions.

With continued research, the authors anticipate refining their predictive model, perhaps integrating additional biomarkers or clinical parameters that further enhance its reliability. Future studies could explore the potential of combining ETCOc with other variables, facilitating an even more comprehensive understanding of jaundice in newborns. This could lead to developments in clinical guidelines that reflect a nuanced approach to managing hyperbilirubinemia, paving the way for improved outcomes.

As the medical community begins to adopt these findings, the hope is that they will inspire a broader discussion around the importance of early detection and intervention across various neonatal conditions. The research team’s work serves as a powerful reminder of the impact that data-driven insights can have in clinical settings, particularly when it comes to safeguarding the health of our most vulnerable populations.

In summary, this research not only highlights the predictive potential of early postnatal ETCOc levels but also sets the stage for further investigation into improving strategies for managing jaundice in newborns. The promise of this study lies in its ability to usher in a new era of personalized pediatric care, where early interventions could dramatically transform the outcomes for countless infants facing this condition. The integration of innovative approaches, like the one proposed, may ultimately lead to advances in neonatal health that resonate across generations.

The significance of this work is compounded by the rising global interest in improving neonatal care frameworks, particularly in developing countries where access to phototherapy may be limited. By refining predictive measures, the study not only advocates for better health outcomes but also emphasizes the potential for cost-effectiveness in treatment paradigms. Consequently, this research lays a foundation for further exploration into how such innovative practices can be implemented universally, ensuring equity in healthcare for all newborns.

As healthcare continues to evolve, the findings from this pivotal study underscore the critical importance of understanding the biological underpinnings of common neonatal conditions. With the potential for establishing new standards in the clinical management of jaundice, this research has the capacity to inspire widespread change. As such, it opens the door for future inquiries that build upon this foundational work, allowing new generations of clinicians to adopt a more refined, data-driven approach to neonatal care.

In conclusion, the study represents a significant leap forward in the prediction and management of jaundice in newborns, emphasizing the role of scientific inquiry in enhancing pediatric healthcare. The detailed analysis and results provide a compelling case for integrating early ETCOc assessments into clinical practice, promising to improve patient outcomes and advance the field of neonatology. As the conversation surrounding neonatal healthcare continues to grow, this research will undoubtedly serve as a critical reference point for future innovations and advancements in the management of newborn conditions.

Subject of Research: Phototherapy prediction through early postnatal ETCOc assessments in Chinese newborns.

Article Title: The prediction of phototherapy by early postnatal ETCOc in Chinese newborns.

Article References: Yang, G., Deng, L., Zhang, K. et al. The prediction of phototherapy by early postnatal ETCOc in Chinese newborns. BMC Pediatr 25, 966 (2025). https://doi.org/10.1186/s12887-025-06073-x

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12887-025-06073-x

Keywords: jaundice, phototherapy, newborn care, ETCOc, predictive model, hyperbilirubinemia, neonatal health, pediatric care, early detection, bilirubin, hemolysis, clinical guidelines, personalized medicine, healthcare innovation.

Neonatal hyperbilirubinemia, the medical term for elevated bilirubin levels in newborns, represents one of the most common conditions requiring clinical attention during the earliest days of life. Bilirubin accumulation manifests as jaundice, causing a yellow discoloration of the skin and mucous membranes. While often benign and self-limiting, severe hyperbilirubinemia can lead to critical neurological damage if left untreated. Phototherapy—the use of specific wavelengths of light to convert bilirubin into soluble isomers that can be excreted without conjugation—is the gold standard treatment, effectively reducing serum bilirubin levels and preventing kernicterus.

Traditional phototherapy administration usually occurs in hospital settings, often requiring prolonged stay in neonatal care units. However, hospitalization can induce significant parental stress, disrupt early bonding, and carry associated risks such as nosocomial infections. Recognizing these challenges, Spaan et al.’s study investigates whether home-based phototherapy could serve as an equally efficacious, safer, and more humane alternative, thus redefining postnatal care paradigms.

The methodology employed in this review is a model of rigorous scientific synthesis, combining both quantitative data from meta-analyses and qualitative insights from patient and caregiver experiences. The investigators sifted through extensive databases, meticulously selecting randomized controlled trials, cohort studies, and qualitative reports meeting stringent inclusion criteria. Such mixed methods analysis allowed for an enriched understanding not only of treatment outcomes but also of contextual factors influencing therapy success in the home environment.

One of the most compelling findings emerging from this comprehensive analysis is the equivalency in therapeutic success rates between hospital and home phototherapy. Serum bilirubin reduction trajectories were remarkably similar, affirming that with proper guidance and equipment, phototherapy applied at home can substantially alleviate jaundice with no statistically significant compromise on clinical effectiveness. This finding challenges entrenched clinical dogmas emphasizing hospitalization for all cases requiring phototherapy.

Safety profile analysis further enhanced the appeal of home phototherapy. Adverse events were rare across both settings, and when present, they were mild and manageable. Crucially, the study emphasizes that patient selection criteria and parental education are paramount; when families receive thorough training on device operation, recognition of warning signs, and adherence monitoring, home phototherapy proves to be a safe backdrop for jaundice management.

The review also offers an exploration of parental psychological outcomes, a dimension often overlooked in neonatal care research. Parents administering phototherapy at home reported decreased anxiety levels, higher satisfaction, and strengthened infant–parent bonding experiences. These psychosocial benefits ripple through the early postnatal period, potentially positively influencing long-term family dynamics and infant development.

From a health economics standpoint, home phototherapy emerges as a potential cost-saving strategy by reducing hospitalization days, relieving pressure on neonatal intensive care units, and decreasing associated healthcare expenditures. These findings resonate with broader healthcare system goals focused on efficiency, patient-centered care, and resource optimization.

Despite these promising results, the authors caution against wholesale adoption without adherence to safety protocols and infrastructure support. Universal access to calibrated phototherapy devices, reliable communication channels for clinical supervision, and emergency response readiness remain non-negotiable requirements to ensure favorable outcomes. The research highlights gaps in technology standardization and healthcare policy frameworks that must be addressed for scalable home phototherapy programs.

Technological advancements in portable phototherapy units examined in this review underscore the critical role of engineering innovations in enabling home treatment. The development of energy-efficient, low-heat-emission devices with user-friendly interfaces diminishes barriers to use and enhances compliance, reflecting an interdisciplinary synergy between clinical medicine and biomedical engineering.

Furthermore, the study delves into the nuances of light dosimetry and its impact on treatment efficacy. Phototherapy operates optimally within specific wavelengths, typically blue light around 460-490 nm. The ability of home devices to deliver consistent irradiance, maintain appropriate distance from the infant’s skin, and achieve sufficient body surface exposure without provoking overheating or dehydration is vital. The review analyzes these parameters, underscoring the need for robust device validation before widespread deployment.

Another pivotal aspect explored is the integration of telemedicine into home phototherapy regimens. Remote monitoring and virtual consultations enable healthcare providers to track bilirubin levels, troubleshoot device issues, and provide timely interventions. Although still in its infancy, such digital health applications exhibit the potential to bridge gaps inherent in home-based care models, ensuring safety nets without necessitating hospital visits.

The authors also reflect on disparities in access to home phototherapy, citing socioeconomic and geographic factors influencing feasibility. While urban, well-resourced populations may benefit disproportionately, efforts must be channelized toward equitable dissemination, especially in low- and middle-income countries where neonatal jaundice contributes substantially to infant morbidity and mortality.

In summarizing, this pioneering synthesis by Spaan and colleagues heralds an important paradigm shift by demonstrating that with meticulous preparation, home phototherapy constitutes a viable alternative to hospital care for neonatal hyperbilirubinemia. Their findings challenge conventional treatment models, advocate for patient-centric approaches, and highlight the confluence of medical science and technological innovation.

The study opens fertile ground for future research directions, including longitudinal assessments of neurodevelopmental outcomes following home phototherapy, development of standardized training modules for caregivers, and exploration of health system integration strategies. Policymakers and clinicians alike stand at a crossroads, empowered by robust evidence to rethink neonatal jaundice management protocols.

As healthcare continues to evolve toward personalization and decentralization, the emerging evidence supporting home phototherapy exemplifies how careful scientific inquiry can translate into practical, life-enhancing interventions. This research holds profound implications for millions of newborns and their families worldwide, promising safer, more comfortable, and potentially more cost-effective treatment pathways that honor the delicate nature of early life.

Subject of Research: Neonatal hyperbilirubinemia treatment via home phototherapy.

Article Title: Home phototherapy for neonatal hyperbilirubinemia: a mixed methods systematic review and meta-analysis.

Article References:
Spaan, J., Westenberg, L.E.H., Ista, E. et al. Home phototherapy for neonatal hyperbilirubinemia: a mixed methods systematic review and meta-analysis. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04313-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04313-5